What is Survodutide?
Survodutide is a long-acting peptide co-agonist discovered by Zealand Pharma and developed by Boehringer Ingelheim. It was designed to provide a more comprehensive metabolic intervention than pure GLP-1 agonists by adding the energy-expenditure benefits of glucagon signaling.
In 2024, it made headlines with Phase 2 trial results showing that up to 83% of subjects with MASH (liver inflammation) achieved significant clinical improvement, positioning it as a potential first-in-class therapy for metabolic liver disease.
⚗️ Key Research Facts
- Type: GLP-1 / Glucagon Dual Receptor Agonist
- Primary Goal: MASH (Metabolic Dysfunction-Associated Steatohepatitis)
- Fibrosis Impact: Up to 64.5% improvement in F2/F3 stages
- Status: Phase 3 Clinical Development
Mechanism: The Dual-Action Pathway
Survodutide works by activating two critical receptors simultaneously:
- GLP-1 Receptor: Reduces appetite, improves glucose-dependent insulin secretion, and slows gastric emptying (the classic "Ozempic" effect).
- Glucagon Receptor: Increases energy expenditure, enhances hepatic (liver) fat breakdown, and promotes lipolysis.
This "push-pull" mechanism allows the body to decrease caloric intake while actively increasing the rate at which it burns fat, particularly in the liver.
MASH & Liver Fat Results
The 2024 Phase 2 trial data for **MASH** (formerly known as NASH) showed unprecedented results:
83% MASH Improvement
The majority of subjects saw a 2-point or greater reduction in liver inflammation scores without worsening of fibrosis.
87% Fat Reduction
Nearly 9 out of 10 subjects achieved at least a 30% reduction in liver fat content within 48 weeks.
Obesity & Weight Loss Data
While liver health is its primary focus, Survodutide is also a potent weight-loss agent. In obesity-specific trials, participants lost up to 19% of their body weight at the 4.8 mg and 6.0 mg doses. This rivals the efficacy of top-tier triple agonists and suggests it may be superior to standard GLP-1 monotherapies for those with concurrent metabolic issues.
Research Protocols & Dosing
- Administration: Once-weekly subcutaneous injection.
- Maintenance Dose: Research doses range from 2.4 mg to 6.0 mg.
- Escalation: Typically starts at 0.3 mg and increases every 4 weeks.
- Side Effects: Primarily gastrointestinal (nausea, vomiting), similar to other GLP-1 receptor agonists.
- Storage: Lyophilized powder in the freezer. Reconstituted solution in the refrigerator.
Frequently Asked Questions
How does it differ from Tirzepatide?
Tirzepatide targets GLP-1 and GIP. Survodutide targets GLP-1 and **Glucagon**. While both help with weight, the glucagon component in Survodutide is specifically effective at "melting" liver fat and increasing the metabolic rate.
Does glucagon increase blood sugar?
On its own, yes. However, when co-administered with a GLP-1 agonist like in Survodutide, the glucose-lowering effects of the GLP-1 component balance the glucagon, resulting in overall improved glycemic control in research models.
Where to buy Survodutide in Canada?
Nūmira Peptides provides high-purity Survodutide for laboratory and clinical research purposes. Shop Survodutide →
Survodutide — Research Grade
Purity >98% · Dual GLP-1/Glucagon · Domestic Canadian shipping
Shop Survodutide →